Evidence map›Paper›PMID 29080012›Full record

ArticleEuropean journal of epidemiology2018

Associations of serum 25-hydroxyvitamin D level with incidence of lung cancer and histologic types in Norwegian adults: a case-cohort analysis of the HUNT study.

Yi-Qian Sun, Arnulf Langhammer, Chunsen Wu, Frank Skorpen, Yue Chen, Tom Ivar Lund Nilsen, Pål Richard Romundstad, Xiao-Mei Mai

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Yi-Qian SunDepartment of Clinical and Molecular Medicine (IKOM), NTNU, Norwegian University of Science and Technology, Trondheim, Norway. yi-qian.sun@ntnu.no.ORCID 0000-0002-9634-9236
Arnulf LanghammerDepartment of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Chunsen WuInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Frank SkorpenDepartment of Clinical and Molecular Medicine (IKOM), NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Yue ChenSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Tom Ivar Lund NilsenDepartment of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Pål Richard RomundstadDepartment of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Xiao-Mei MaiDepartment of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Norwegian University of Science and Technology · NOUniversity of Ottawa · CAUniversity of Southern Denmark · DK

Funding

Kreftforeningen 5769155-2015
6 · The paper itself

Abstract

Previous prospective studies have shown inconsistent associations between serum 25-hydroxyvitamin D [25(OH)D] level and lung cancer incidence. The aim of the present study was to explore the associations of serum 25(OH)D levels with incidence of lung cancer overall and different histologic types. We performed a population-based prospective case-cohort study including 696 incident lung cancer cases and 5804 individuals in a subcohort who participated in the second survey of the Nord-Trøndelag Health Study in Norway. Cox proportional hazards regression models counting for the case-cohort design were used to estimate hazard ratios (HRs) with 95% confidence interval (CIs) for lung cancer overall or histologic types in relation to serum 25(OH)D levels. Compared with the fourth season-specific quartile of 25(OH)D (median 68.0 nmol/L), lower 25(OH)D levels were not associated with the incidence of overall, small or squamous cell lung cancer. However, the risk of adenocarcinoma was lower in the second and third quartiles (median 39.9 and 51.5 nmol/L) compared with the fourth quartile, with HRs of 0.63 (95% CI 0.41-0.98) and 0.58 (0.38-0.88), respectively. The associations of lower levels of 25(OH)D with a reduced risk of adenocarcinoma were only observed in the overweight/obese subjects [HRs for second and third quartiles: 0.40 (0.22-0.72) and 0.50 (0.27-0.92)] but not in the normal weight subjects [HRs: 0.95 (0.52-1.75) and 0.60 (0.32-1.10)]. Serum 25(OH)D levels were not associated with the risk of lung cancer in general. The observation that lower 25(OH)D levels were associated with a lower risk of adenocarcinoma should be interpreted with caution.

Indexed as

AdenocarcinomaAgedAged, 80 and overCohort StudiesFemaleHumansIncidenceLung NeoplasmsMaleMiddle AgedNorwayProspective StudiesVitamin D25-hydroxyvitamin DVitamin DCase-cohort studyHistologic typesLung cancerPulmonary adenocarcinomaSerum 25-hydroxyvitamin D [25(OH)D]Vitamin D

Identifiers

PMID29080012
OpenAlexW2766120392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.